Full Press Release Details
Creative Medical Technology Holdings
Announces Creation of Amniotic Fluid
Stem Cell Focused Subsidiary AmnioStem LLC
Clinical Stage Stem Cell Therapeutics
Company Expands Regenerative Medicine Portfolio to 'Off-the-Shelf Allogeneic Stem Cell Products
Phoenix, AZ, November 16, 2016-Creative Medical
Technology Holdings (OTCQB:CELZ) announced today the formation of a wholly-owned subsidiary, AmnioStem LLC, focused on the development
of therapeutic products derived from amniotic fluid stem cells. These stem cells are subject of issued US patent #7,569,385, which
was licensed from the University of California, San Diego (UCSD).
This type of stem cell is considered an adult stem cell since
no fetal damage occurs during its extraction. Amniotic fluid stem cells have been demonstrated by scientists from independent research
institutions to be effective in animal models of stroke1, heart attack2, liver failure3, colitis4,
diabetes5, emphysema6, and kidney injury7. An important activity of amniotic fluid stem cells
is that cells derived from one person can be used to treat other people, making them "universal donor" stem cells.
"To date, Creative Medical Technology Holdings has focused
on developing therapies using stem cells derived from the same patient. This allows for personalized treatment of conditions such
as erectile dysfunction, for which we are running a clinical trial, as well as male infertility, miscarriages, and female infertility,
which we are in preclinical stages of development. Based on in-depth discussions with our Scientific Advisory Board and experts
in the field, we have decided that amniotic fluid stem cells possess the ideal characteristics for us to select as our source of
allogeneic or 'universal donor stem cells to develop for therapeutic applications," said Timothy
Warbington, President & CEO of Creative Medical Technology Holdings.
The amniotic fluid is the liquid that surrounds the fetus and
provides nutrient and growth factor support for its development. Amniotic fluid is obtained from routine amniocentesis procedures
and is regarded as medical waste.
"Regenerative medicine has substantially advanced through
the use of allogeneic stem cells in conditions ranging from post-stroke recovery to heart failure. The majority of companies developing
allogeneic stem cells have focused on bone marrow as a starting source. I am optimistic that amniotic fluid stem cells could possess
superior therapeutic activity, in part due to the fact that these cells are younger and conceptually more potent," said Amit
Patel, MS, M.D., director of Tissue Engineering and Regenerative Medicine at the University of Utah, and board member of Creative
Medical Technology Holdings.
"Numerous studies have shown that after a stroke, the
injured brain produces chemicals which selectively attract stem cells," said Thomas Ichim, Ph.D., and board member of Creative
Medical Technology Holdings. "Through specific manipulation of our amniotic fluid derived stem cells, we believe that we
are in a position to develop a therapy which allows for intravenous administration of stem cells, which could home into the injured
brain and kick-start a process of healing. Current stem cell approaches to stroke require direct implantation of the stem cells
into the brain. By developing an intravenous stem cell approach we believe we can overcome several of the hurdles that prevent
widespread use of stem cells in stroke patients."
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a clinical stage
biotechnology company currently trading on the OTCQB under the ticker symbol CELZ. For further information about the company go
to creativemedicaltechnology.com.
Forward-Looking Statements
OTC Markets has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited
to comments regarding the indicated uses of stem cells derived from amniotic fluid for therapeutic applications for stroke or other
patients, timing and content of possible clinical trials to gain approval for use of the amniotic fluid stem cells, marketing efforts,
funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties.
Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed
by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's
website at www.sec.gov.
Creative Medical Technology Holdings, Inc.
Timothy Warbington, CEO & President
SOURCE Creative Medical Technology Holdings, Inc.
to the reports listed below are a service to those interested in this information. While we believe these reports to be relevant
and accurate, we do not endorse these reports and can make no guarantee as to their accuracy or completeness. Users visit the websites